Chris Boshoff: Positive topline overall survival results for our combination regimen in men with metastatic castration-resistant prostate cancer

Chris Boshoff, Chief Oncology Officer and Executive Vice President at Pfizer, shared a post on LinkedIn:

“I’m excited to share that we have announced positive topline overall survival results for our combination regimen from our Phase 3 study in men with metastatic castration-resistant prostate cancer (mCRPC).

mCRPC is the most advanced and aggressive stage of prostate cancer, and patients are in high unmet need for additional effective treatment options.

These potentially practice-changing results underscore our long-standing commitment to improving outcomes for people living with prostate cancer.

Thank you to all of my colleagues at Pfizer, investigators, patients and their families for their role in this positive trial.”

Read more.